Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Lung
Descriptor: Mutation of Met


Reference Number: 225

Ma, P.C. et al.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272-81 (2003).


PubMed link      E-mail link

Reference Number: 333
Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res65, 1479-88 (2005)
PubMed link      E-mail link

Reference Number: 341
Zaffaroni D, Spinola M, Galvan A, Falvella FS, Pazzaglia S, Saran A, Mancuso MT, Galbiati F, Pignatiello C, Cabrera W, Ibanez O, Manenti G, Dragani TA. Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis. Oncogene  24, 1084-90 (2005)
PubMed link      E-mail link

Reference Number: 388
Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, Holcomb T, Pujara K, Stinson J, Fu L, Severin C, Rangell L, Schwall R, Amler L, Wickramasinghe D, Yauch R. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 66, 283-9 (2006)
PubMed link      E-mail link

Reference Number: 440
Tengs T, Lee JC, Guillermo Paez J, Zhao X, Laframboise T, Giannoukos G, Thomas RK. A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing. Cancer Lett. 239, 227-33 (2006)
PubMed link      E-mail link

Reference Number: 641
Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM, Massard G, Quoix E, Oudet P, Gaub MP. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol. 3, 331-9 (2008)
PubMed link      E-mail link

Reference Number: 691
Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 99, 2280-5 (2008)
PubMed link      E-mail link

Reference Number: 707

Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol. 4, 5-11 (2009)

PubMed link      E-mail link

Reference Number: 708
Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 47, 1025-37 (2008)
PubMed link      E-mail link

Reference Number: 898
Go H, Jeon YK, Park HJ, Sung SW, Seo JW, Chung DH. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 3, 305-13 (2010)
PubMed link      E-mail link

Reference Number: 899
Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, Sattler M, Vokes EE, Wang YC, Salgia R. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 5, e8972 (2010)
PubMed link      E-mail link

Reference Number: 986
Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One. 5, e13586 (2010)
PubMed link      E-mail link

Reference Number: 1030
Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, Yamaguchi H, Nakagawa K. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol. 6, 1624-31 (2011)
PubMed link      E-mail link

Reference Number: 1087
Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, Ferguson MK, Natarajan V, Wang YC, Garcia JG, Vokes EE, Salgia R. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 15, 5714-23 (2009)
PubMed link      E-mail link

Reference Number: 1088
Salgia R. Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol. 36(2 Suppl 1), S52-8 (2009)
PubMed link      E-mail link

Reference Number: 1152
Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, Bellezza G, Tofanetti FR, Siggillino A, Baldelli E, Flacco A, Giuffrida D, Sidoni A, Crinò L. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol. 69, 1289-99 (2012)
PubMed link      E-mail link

Reference Number: 1162
Gumustekin M, Kargi A, Bulut G, Gozukizil A, Ulukus C, Oztop I, Atabey N. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res. 18, 209-18 (2012)
PubMed link      E-mail link

Reference Number: 1289
Voortman J, Harada T, Chang RP, Killian JK, Suuriniemi M, Smith WI, Meltzer PS, Lucchi M, Wang Y, Giaccone G. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. Curr Pharm Des. 19, 833-40 (2013)
PubMed link      E-mail link

Reference Number: 1415
Jiang L1, Huang J, Morehouse C, Zhu W, Korolevich S, Sui D, Ge X, Lehmann K, Liu Z, Kiefer C, Czapiga M, Su X, Brohawn P, Gu Y, Higgs BW, Yao Y. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. Cancer Genet. 206, 330-9 (2013)
PubMed link      E-mail link

Reference Number: 1474
Xia N, An J, Jiang QQ, Li M, Tan J, Hu CP. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. Exp Lung Res. 39, 328-35 (2013)
PubMed link      E-mail link

Reference Number: 1500
Boland JM, Jang JS, Li J, Lee AM, Wampfler JA, Erickson-Johnson MR, Soares I, Yang P, Jen J, Oliveira AM, Yi ES. MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol. 8, 574-81 (2013)
PubMed link      E-mail link

Reference Number: 1673
Tuononen K, Kero M, Mäki-Nevala S, Sarhadi VK, Tikkanen M, Wirtanen T, Rönty M, Knuuttila A, Knuutila S. ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients. Genes Chromosomes Cancer. 53, 895-901 (2014)
PubMed link      E-mail link

Reference Number: 1674
Vieira T, Antoine M, Ruppert AM, Fallet V, Duruisseaux M, Giroux Leprieur E, Poulot V, Rabbe N, Sclick L, Beau-Faller M, Lacave R, Lavole A, Cadranel J, Wislez M. Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung. Lung Cancer. 85, 276-81 (2014)
PubMed link      E-mail link

Reference Number: 1676
Bordi P, Tiseo M, Barbieri F, Bavieri M, Sartori G, Marchetti A, Buttitta F, Bortesi B, Ambrosini-Spaltro A, Gnetti L, Silini EM, Ardizzoni A, Rossi G. Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients. Lung Cancer. 86, 324-8 (2014)
PubMed link      E-mail link

Reference Number: 1773
Dhanasekaran SM, Balbin OA, Chen G, Nadal E, Kalyana-Sundaram S, Pan J, Veeneman B, Cao X, Malik R, Vats P, Wang R, Huang S, Zhong J, Jing X, Iyer M, Wu YM, Harms PW, Lin J, Reddy R, Brennan C, Palanisamy N, Chang AC, Truini A, Truini M, Robinson DR, Beer DG, Chinnaiyan AM. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun. 5, 5893 (2014)
PubMed link      E-mail link

Reference Number: 1778
Cao X, Hong X, Jia X, Zhang L, Chen G. Single-nucleotide polymorphism rs41736 located in MET was significantly associated with prognosis of small cell lung cancer patients. Med Oncol. 31, 333 (2014)
PubMed link      E-mail link

Reference Number: 1794
Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, Borsu L, Schultz N, Berger MF, Rudin CM, Ladanyi M. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 5, 842-9 (2015)
PubMed link      E-mail link